489 related articles for article (PubMed ID: 19814586)
1. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
[TBL] [Abstract][Full Text] [Related]
2. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Nalamachu S; Hassman D; Wallace MS; Dumble S; Derrick R; Howell J
Curr Med Res Opin; 2011 Mar; 27(3):519-30. PubMed ID: 21208151
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
[TBL] [Abstract][Full Text] [Related]
8. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.
Lennernäs B; Frank-Lissbrant I; Lennernäs H; Kälkner KM; Derrick R; Howell J
Palliat Med; 2010 Apr; 24(3):286-93. PubMed ID: 20015921
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
14. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
